This article is more than 5 years old. Information may no longer be current.

Study Evaluating Safety and Efficacy of UCART123 in Patients With Acute Myeloid Leukemia

Issue: April 2019 2019

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Phase 1, first-in-human, open-label, dose-finding study of UCART123 administered intravenously to patients with acute myeloid leukemia, followed by a dose-escalation phase in patients with relapsed or refractory AML and a dose-expansion phase in patients with relapsed or refractory AML, and in poor-prognosis, newly diagnosed patients with AML patients in the European Leukemia Net adverse genetic risk group.